PROSTATE CANCER
Over 100 people die of prostate cancer every day in the United States. There are 180,000 new incidences every year at total treatment cost of 5 billion dollars. Targeted cryablation offers an effective treatment modality. A recent investigation of 120 prostate cancer patients treated by targeted cryoablation proves that 99% patients do not recur 6 months after operation and 97% do not recur 12 months after operation.
· FDA approved targeted cryoablation for treatment of prostate cancer.
· Targeted cryoablation has reinbured by Medicare in US since 1999.
· Minimally invasive, no pain, few complications, short hospital stay, rapid recovery, good curative effects.
· Currently, it has been used in more than 300 US hospitals.
Benign Prostate Hyperplasia (BPH) BPH patients occur to 50% of males over 50 year-old and 80% over 80 year-old in USA. The cause of BPH is blocking of urethra by prostate hyperplasia. Targeted cryoablation allows physicians to perform treatment in chosen parts of BPH. It can rapidly improve urination and relieve pains and other symptoms of these patients. |
